Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 14:10:60.
doi: 10.1186/s13256-016-0837-3.

An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report

Debora de Melo Gagliato  1 , Rudinei Diogo Marques Linck  2 , Regis Otaviano Franca Bezerra  2 , Mirela Souto  2 , Gabriel Lima Lopes  2 , Glauco Baiocchi  3 , Max Senna Mano  2
Affiliations
Review

An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report

Debora de Melo Gagliato et al. J Med Case Rep. .

Abstract

Background: Uterine carcinosarcoma is well known for its aggressive behavior. There is little evidence regarding the gold standard combination chemotherapy in metastatic or locally advanced carcinosarcoma, due to poor survival outcomes obtained with conventional scheduled chemotherapy. This case report represents the first-ever reported objective response to a metronomic chemotherapy regimen and adds to the current literature.

Case presentation: We describe a case of a Caucasian woman diagnosed with metastatic carcinosarcoma that had already been treated with multiple lines of conventional chemotherapy, with progressive disease. This patient had a surprising clinical and imaging response when treated with oral metronomic cyclophosphamide.

Conclusions: We reviewed the mechanism of action implicated in metronomic chemotherapy, and correlated it with the biology of disease in carcinosarcoma. This information may add to the current literature, providing important insights to future clinical trials in this patient population.

Keywords: Antiangiogenic therapy; Metronomic chemotherapy; Uterine carcinosarcoma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
T2- and diffusion-weighted magnetic resonance imaging scans (b = 600). In the top row, blue arrows indicate hepatic lesions and red arrows indicate abdominal lymphadenopathy at baseline. In the bottom row, scans taken after metronomic chemotherapy treatment show a major reduction at the hepatic lesions (green arrows) as well as at the abdominal lymphadenopathy
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93(1):204–8. doi: 10.1016/j.ygyno.2003.12.029. - DOI - PubMed
    1. Cimbaluk D, Rotmensch J, Scudiere J, Gown A, Bitterman P. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2007;105(1):138–44. doi: 10.1016/j.ygyno.2006.11.001. - DOI - PubMed
    1. Giuntoli RL, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89(3):460–9. doi: 10.1016/S0090-8258(03)00137-9. - DOI - PubMed
    1. Arend R, Doneza JA, Wright JD. Uterine carcinosarcoma. Curr Opin Oncol. 2011;23(5):531–6. - PubMed
    1. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413–9. doi: 10.1023/A:1008329910362. - DOI - PubMed

MeSH terms

Substances